The microfluidic serological assay combining nano-interstices and digitized flow control is capable of detecting anti-N IgG and IgM in only 5 min with a sensitivity and specificity of 91.67% and 100% validated by testing 152 serum samples as described by Lee et al. However, the semi-automated multiplexed microfluidic technique takes a comparatively longer time (2.6 h) to detect antibodies with a sensitivity of 95% and specificity of 91% based on testing serum samples collected from 66 COVID-19 patients [23,25]. The gene discussed is CD40LG; the disease is COVID-19.